Loading clinical trials...
Loading clinical trials...
Evaluation of eGFR, Determined by Cystatin C and Creatinine, and mGFR, Measured by Iohexol Clearance, in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery
Conditions
Interventions
mGFR by iohexol clearance
Locations
6
United States
CB Flock Research
Mobile, Alabama, United States
Valley Clinical Trials
Covina, California, United States
Valley Clinical Trials
Northridge, California, United States
Multi-Specialty Research Associates, Inc.
Lake City, Florida, United States
Advance Medical Research
St. Petersburg, Florida, United States
Duke University Medical Center
Durham, North Carolina, United States
Start Date
February 21, 2020
Primary Completion Date
February 25, 2021
Completion Date
March 26, 2021
Last Updated
July 16, 2021
NCT05573633
NCT07418242
NCT07287345
NCT06474754
NCT06986187
NCT05879432
Lead Sponsor
Quark Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions